Utility of Targeted Positron Emission Tomography Imaging to Predict Schwannoma Growth in a Murine Tumor Model.
HER2/Neu
PET imaging
VEGFR2
immunohistochemistry
murine model
vestibular schwannoma
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
14 Aug 2023
14 Aug 2023
Historique:
revised:
31
05
2023
received:
24
01
2023
accepted:
14
07
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
aheadofprint
Résumé
To identify if targeted positron emission tomography (PET) imaging with radiolabeled antibodies can predict tumor growth rate and ultimate tumor size in a murine flank schwannoma model. Animal research study. Rat schwannoma cells were cultured and implanted into 40 athymic nude mice. Once tumors reached 5 mm in diameter, 30 mice were injected with zirconium-89 labeled antibodies (HER2/Neu, vascular endothelial growth factor receptor 2 (VEGFR2), or IgG isotype). PET/CT was performed, and standardized uptake values (SUV) were recorded. Tumors were serially measured until mice were sacrificed per IACUC protocol. Statistical analysis was performed to measure correlations between SUV values, tumor size, and growth. Mean tumor sizes in mm In a murine schwannoma model, immunotargeted PET imaging with anti-HER2/Neu antibodies predicted tumor growth rate and final tumor size. Laryngoscope, 2023.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The American Laryngological, Rhinological and Otological Society, Inc.
Références
Marinelli JP, Lohse CM, Grossardt BR, Lane JI, Carlson ML. Rising incidence of sporadic vestibular schwannoma: true biological shift versus simply greater detection. Otol Neurotol. 2020;41(6):813-847. https://doi.org/10.1097/MAO.0000000000002626.
Tos M, Thomsen J. Epidemiology of acoustic neuromas. J Laryngol Otol. 1984;98(7):685-692. https://doi.org/10.1017/s0022215100147292.
Selesnick SH, Johnson G. Radiologic surveillance of acoustic neuromas. Am J Otol. 1998;19(6):846-849.
Nikolopoulos TP, Fortnum H, O'Donoghue G, Baguley D. Acoustic neuroma growth: a systematic review of the evidence. Otol Neurotol. 2010;31(3):478-485. https://doi.org/10.1097/MAO.0b013e3181d279a3.
van Oostenbrugge T, Mulders P. Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab. Curr Opin Urol. 2021;31(3):249-254. https://doi.org/10.1097/MOU.0000000000000872.
Warram JM, de Boer E, Sorace AG, et al. Antibody-based imaging strategies for cancer. Cancer Metastasis Rev. 2014;33(2-3):809-822. https://doi.org/10.1007/s10555-014-9505-5.
Lallemand D, Manent J, Couvelard A, et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene. 2009;28(6):854-865. https://doi.org/10.1038/onc.2008.427.
Taurone S, Bianchi E, Attanasio G, et al. Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue. Mol Med Rep. 2015;12(1):737-745. https://doi.org/10.3892/mmr.2015.3415.
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137. https://doi.org/10.1038/35052073.
Greally M, Kelly CM, Cercek A. HER2: an emerging target in colorectal cancer. Curr Probl Cancer. 2018;42(6):560-571. https://doi.org/10.1016/j.currproblcancer.2018.07.001.
Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17(10):611-625. https://doi.org/10.1038/nrm.2016.87.
Plotkin SR, Duda DG, Muzikansky A, et al. Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J Clin Oncol. 2019;37(35):3446-3454. https://doi.org/10.1200/JCO.19.01367.
Morrison DR, Sorace AG, Hamilton E, et al. Predicting schwannoma growth in a tumor model using targeted imaging. Otol Neurotol. 2021;42(5):e615-e623. https://doi.org/10.1097/mao.0000000000003063.
Mallum A, Mkhize T, Akudugu JM, Ngwa W, Vorster M. The role of positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning: a literature review. Diagnostics (Basel). 2022;13(1):53. https://doi.org/10.3390/diagnostics13010053.
Johnson DR, Hunt CH, Nathan MA, et al. Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. J Neurooncol. 2018;136(2):373-378. https://doi.org/10.1007/s11060-017-2661-z.
Queern SL, Aweda TA, Massicano AVF, et al. Production of Zr-89 using sputtered yttrium coin targets (89)Zr using sputtered yttrium coin targets. Nucl Med Biol. 2017;50:11-16. https://doi.org/10.1016/j.nucmedbio.2017.03.004.
Schnurman Z, Nakamura A, McQuinn MW, Golfinos JG, Roland JT, Kondziolka D. Volumetric growth rates of untreated vestibular schwannomas. J Neurosurg. 2019;133:1-7. https://doi.org/10.3171/2019.5.JNS1923.
Paldor I, Chen AS, Kaye AH. Growth rate of vestibular schwannoma. J Clin Neurosci. 2016;32:1-8. https://doi.org/10.1016/j.jocn.2016.05.003.
Tschudi DC, Linder TE, Fisch U. Conservative management of unilateral acoustic neuromas. Am J Otol. 2000;21(5):722-728.
van de Langenberg R, de Bondt BJ, Nelemans PJ, Dohmen AJ, Baumert BG, Stokroos RJ. Predictors of volumetric growth and auditory deterioration in vestibular schwannomas followed in a wait and scan policy. Otol Neurotol. 2011;32(2):338-344. https://doi.org/10.1097/MAO.0b013e3182040d9f.
Lovato A, Garcia Ibanez E, Garcia Ibanez L, de Filippis C. Tumor growth rate: a new prognostic indicator of hearing preservation in vestibular schwannoma surgery. Laryngoscope. 2019;129(10):2378-2383. https://doi.org/10.1002/lary.27805.
Patel NS, Huang AE, Dowling EM, et al. The influence of vestibular schwannoma tumor volume and growth on hearing loss. Otolaryngol Head Neck Surg. 2020;162(4):530-537. https://doi.org/10.1177/0194599819900396.
Reinert CP, Schuhmann MU, Bender B, et al. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. Eur J Nucl Med Mol Imaging. 2019;46(3):776-787. https://doi.org/10.1007/s00259-018-4227-5.
Anton-Rodriguez JM, Lewis D, Djoukhadar I, et al. [18F]fluorothymidine and [18F]fluorodeoxyglucose PET imaging demonstrates uptake and differentiates growth in neurofibromatosis 2 related vestibular schwannoma. Otol Neurotol. 2019;40(6):826-835. https://doi.org/10.1097/MAO.0000000000002272.
Zhou Y, Zhao W, Tian L, Yu J, Yuan Y, Wang J. The prediction of the tumor size of a vestibular schwannoma by clinical performance and vestibular function tests. J Neurooncol. 2018;140(3):679-686. https://doi.org/10.1007/s11060-018-2998-y.
Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8(4):304-310. https://doi.org/10.1016/S1470-2045(07)70044-X.
Hekman MCH, Rijpkema M, Aarntzen EH, et al. Positron emission tomography/computed tomography with (89)Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion. Eur Urol. 2018;74(3):257-260. https://doi.org/10.1016/j.eururo.2018.04.026.
Verhoeff SR, van Es SC, Boon E, et al. Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019;46(9):1931-1939. https://doi.org/10.1007/s00259-019-04358-9.
Carmon KS, Azhdarinia A. Application of Immuno-PET in antibody-drug conjugate development. Mol Imaging. 2018;17:1536012118801223. https://doi.org/10.1177/1536012118801223.
Gebhart G, Lamberts LE, Wimana Z, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27(4):619-624. https://doi.org/10.1093/annonc/mdv577.
Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2010;97(3):409-418. https://doi.org/10.1007/s11060-009-0038-7.
Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(15):3262-3269. https://doi.org/10.1200/JCO.2002.11.017.